Skip to content

Patients › General-Health

سوزش اور ریموٹائڈ آرتھرائٹس

PDF Evidence

Rheumatoid, psoriatic and gouty arthritis affecting the hand, wrist and upper limb — what they are, how they are managed, and when surgery helps.

Updated Sep 2026
ایک ہاتھ جس میں سوجن انگوٹھے کے جوڑ ہوتے ہیں۔
سوزش والی آرتھرائٹس مشترکہ استر پر حملہ کرتی ہے، جس کی وجہ سے سوجن، سختی اور اگر علاج نہ کیا جائے تو مشترکہ نقصان ہوتا ہے۔ Kieran Hirpara 4.0

اس صفحے کا ترجمہ مشین سے کیا گیا ہے اور ابھی تک کسی ڈاکٹر نے اس کی جانچ نہیں کی۔ انگریزی نسخہ ہی مستند ہے۔

آپ کیا محسوس کر رہے ہیں

سوزش والی گٹھائی، بشمول رومٹوائڈ گٹھائی، ایک ایسی حالت ہے جہاں آپ کا مدافعتی نظام آپ کے جوڑوں کی استر پر حملہ کرتا ہے۔ یہ سوجن، درد اور سختی کا سبب بنتا ہے، اکثر ایک ہی وقت میں کئی جوڑوں میں. اسی بیماری کا عمل آپ کے کندھے، کہنی، کلائی، ہپ، گھٹنے یا ٹخنوں کو متاثر کر سکتا ہے.

درد صبح کے وقت زیادہ ہوتا ہے اور دن کے دوران حرکت کرتے وقت کم ہو سکتا ہے۔ آرام سے فلیش ختم ہوسکتا ہے، لیکن تھوڑی دیر کے لئے بیٹھنے کے بعد سختی اکثر واپس آتی ہے. بہت سے لوگ محسوس کرتے ہیں کہ ان کی علامات آتی اور جاتی ہیں، فلیکس کے درمیان پرسکون ادوار کے ساتھ.

جیسا کہ یہ حالت آپ کے جوڑوں کو متاثر کرتی ہے، روزمرہ کے کام مشکل ہو سکتے ہیں۔ [ صفحہ ۲۱ پر تصویر] اگر آپ کے ہپ، گھٹنے یا ٹخنوں کو متاثر کیا جاتا ہے تو طویل فاصلے پر چلنے میں تکلیف ہوسکتی ہے. جب آپ کی کلائی یا کہنی متاثر ہو تو لکھنا، ٹائپ کرنا یا چھوٹی چھوٹی اشیاء کو پکڑنا مشکل ہوسکتا ہے۔

آپ کو خود جوڑوں سے باہر بھی اس حالت کے اثرات محسوس ہو سکتے ہیں۔ مسلسل درد اور سختی کے ساتھ رہنا آپ کے مزاج اور توانائی کی سطح کو متاثر کرسکتا ہے ، اور اس کے نتیجے میں یہ تبدیل ہوسکتا ہے کہ آپ دن میں کتنا درد محسوس کرتے ہیں۔

اگر آپ کے جوڑوں کو وقت گزرنے کے ساتھ ختم ہو گیا ہے تو، جوڑوں کی تبدیلی کا آپریشن درد کو کم کر سکتا ہے اور جوڑوں کے کام کو بہتر بنا سکتا ہے۔ یہ کندھے، کہنی، کلائی، ہپ، گھٹنے اور ٹخنوں پر لاگو ہوتا ہے. حرکت اور راحت کی بحالی اکثر فوری نہیں بلکہ بتدریج ہوتی ہے، اور یہ آپریشن سے پہلے آپ جہاں تھے وہاں سے بنتی ہے۔

چونکہ سوزش کا گٹھیا آپ کے پورے جسم کے ساتھ ساتھ آپ کے جوڑوں کو بھی متاثر کرتا ہے، اس سے آپریشن کے بعد پیچیدگیوں کا تھوڑا سا زیادہ خطرہ لا سکتا ہے۔ آپ کا ڈاکٹر آپ کے ساتھ یہ بات کرے گا کہ آپ کی دیگر ادویات اور صحت کی حالت اس منصوبے میں کس طرح فٹ بیٹھتی ہے۔

اصل میں کیا ہو رہا ہے

ایک صحت مند جوڑ میں، ہڈیوں کے سروں کو ہموار غضروف سے ڈھانپ لیا جاتا ہے، جو ایک پھسلنے والا تکیہ ہے جس کی وجہ سے سطحیں ایک دوسرے پر پھسلتی ہیں۔ مشترکہ کے ارد گرد ایک پتلی استر سیال بناتا ہے جو ہر چیز کو آزادانہ طور پر منتقل رکھتا ہے، ایک دروازے کے قبضے میں تیل کی طرح تھوڑا سا.

سوزش والے گٹھیا کے ساتھ، آپ کا مدافعتی نظام اس استر کو کچھ نقصان دہ سمجھتا ہے اور اس پر حملہ کرتا ہے۔ آپ کے جوڑوں میں پھوٹ پڑتی ہے وقت گزرنے کے ساتھ ساتھ ، جاری سوزش کارٹیلیج کشن کو کھا جاتی ہے اور عضلات کو ہڈیوں سے جوڑنے والی ہڈیوں کو بھی کمزور کر سکتی ہے۔ یہی وجہ ہے کہ صبح کے وقت آپ کے جوڑوں میں سختی محسوس ہوتی ہے، فلرز کیوں آتے اور جاتے ہیں، اور جب جوڑوں کی سطح کھردری ہوتی ہے تو گرفت یا چلنا کیوں مشکل ہوتا ہے۔

چونکہ یہ بیماری آپ کے پورے جسم کو متاثر کرتی ہے نہ کہ صرف ایک سوکھے ہوئے جوڑ کو۔ اس لیے یہ آپ کے کئی جوڑوں کو ایک ساتھ متاثر کر سکتی ہے اور آپ کی ہڈیوں کی مضبوطی اور انفیکشن کے خلاف آپ کے رد عمل کو بھی متاثر کر سکتی ہے۔ سوزش والے جوڑوں پر ہونے والی سرجری میں پیچیدگیوں کا خطرہ صرف سوزش والے جوڑوں پر ہونے والی سرجری کے مقابلے میں تھوڑا زیادہ ہوتا ہے۔ اور آپ کا ڈاکٹر آپ کو آپریشن کی سفارش کرنے سے پہلے آپ کی ادویات اور عمومی صحت کو قریب سے دیکھتا ہے۔

جب مشترکہ بری طرح نقصان پہنچا ہے، مشترکہ متبادل سرجری میں مدد مل سکتی ہے. استعمال شدہ سطحوں کو مصنوعی جوڑ کے ساتھ تبدیل کرنے سے تکلیف دہ رگڑ ختم ہوجاتی ہے۔ رومیٹائڈ آرتھرائٹس والے لوگ جن کے ہپ، گھٹنے یا کندھے کی تبدیلی ہوتی ہے وہ عام طور پر بعد میں کم درد اور بہتر کام کی اطلاع دیتے ہیں، جیسے ہی پہننے اور آنسو آرتھرائٹس والے لوگ کرتے ہیں۔

ہم اس کے بارے میں کیا کر سکتے ہیں

بہت کچھ ہے جو آپ خود کر سکتے ہیں۔ ہلکی، باقاعدگی سے ورزش آپ کے جوڑوں کو متحرک رکھتی ہے اور آپ کے دل اور عمومی صحت کی حفاظت کرتی ہے۔ زیر نگرانی اعلی شدت کے وقفے کی تربیت اور طاقت کی مشق قابل عمل ہیں اور اچھی طرح سے کنٹرول شدہ روماتوئڈ گٹھیا والے افراد کے ذریعہ برداشت کی جاتی ہیں ، لہذا ان کی سفارش کی جاسکتی ہے کہ وہ قلبی اور جسمانی صحت کو بہتر بنائیں۔ جسمانی اور پیشہ ورانہ تھراپی بھی آپ کو روزمرہ کے کاموں کو سنبھالنے میں مدد دے سکتی ہے۔ یہ نقطہ نظر آپ کے لئے کام کر رہے ہیں کہ آیا فیصلہ کرنے سے پہلے کئی ہفتوں کے دوران ایک منصفانہ جانے دینے کے قابل ہیں.

ابتدائی رومیٹائڈ گٹھیا میں دوائیں سب سے زیادہ کام کرتی ہیں۔ انسداد سوزش ادویات اور کورٹیکوسٹیرائڈز درد اور سوجن کو کم کرتے ہیں۔ میتھوٹریکسٹیٹ اور حیاتیاتی ادویات مدافعتی نظام کو پرسکون کرتی ہیں جو آپ کے جوڑوں پر حملہ کر رہا ہے۔ حیاتیاتی ایجنٹ لیبارٹری میں تیار کردہ پروٹین ہیں جو عام طور پر ایک سوزش پیغام رسانی کو نشانہ بناتے ہیں جسے ٹیومر نیکروسس فیکٹر کہا جاتا ہے، اور انہوں نے علاج میں بہترین نتائج دکھائے ہیں۔ چونکہ یہ آپ کے مدافعتی نظام کو کمزور کرتے ہیں، اس لیے انفیکشن کا خطرہ بڑھ جاتا ہے۔ اس لیے آپ کو اپنے ڈاکٹر سے اس بات پر تبادلہ خیال کرنے کی ضرورت ہے۔ جدید طبی انتظام نے ایک حقیقی فرق پیدا کیا ہے: رومیٹائڈ گٹھیا کے لئے انجام دیئے جانے والے مشترکہ تبدیلیوں کی تعداد میں 1995 اور 2010 کے درمیان 48 فیصد کمی واقع ہوئی ہے ، جو بہتر طبی انتظام کی تاثیر سے منسوب ہے۔

اگر آپ کے علامات ان علاج کے باوجود شدید رہتے ہیں تو آپ کا ڈاکٹر آپ کو ماہر تشخیص کے لیے بھیج سکتا ہے۔ آپ کا ڈاکٹر آپ کی ادویات اور عمومی صحت کو قریب سے دیکھے گا، کیونکہ آپریشن کے ارد گرد کچھ ادویات کو روکنے کی ضرورت ہے. مدافعتی نظام کو دبانے والے ادویات عام طور پر سرجری سے کم از کم 1 ہفتہ پہلے اور 1 ہفتہ بعد روک دیئے جاتے ہیں ، اور کورٹیکوسٹیرائڈز پر لوگوں کو عام طور پر آپریشن کے وقت کے ارد گرد ہائیڈروکورٹیسون کی اضافی خوراک کی ضرورت ہوتی ہے۔ کچھ لوگوں کے لئے جن کے جوڑوں کو شدید نقصان پہنچا ہے، کبھی کبھار ایک طریقہ کار پر غور کیا جا سکتا ہے.

کیا توقع کریں

رومیٹائڈ آرتھرائٹس ایک طویل مدتی حالت ہے، اور زیادہ تر لوگوں کے لئے یہ آتی اور جاتی ہے۔ پرسکون ادوار فلیکس کے درمیان رہتے ہیں، اور سوجن اور سختی اچھی طرح سے غائب ہونے کے بجائے بڑھتی اور کم ہوتی ہے. [ صفحہ ۲۱ پر تصویر]

علاج کے بغیر، سوزش آپ کے جوڑوں پر کام کرتی رہتی ہے۔ مشترکہ نقصان عام طور پر پہلے یا دوسرے سال کے اندر شروع ہوتا ہے اور وہاں سے جاری رہتا ہے. وقت کے ساتھ یہ درد کے طور پر ظاہر ہوتا ہے جب آپ مشترکہ استعمال کرتے ہیں، اور جوڑوں آہستہ آہستہ شکل تبدیل کر سکتے ہیں. ابتدائی علاج اسی وجہ سے اہم ہے: جلد شروع ہونے والی ادویات سوزش کو کم کر سکتی ہیں اس سے پہلے کہ یہ مشترکہ سطحوں کو ختم کر دے۔

اچھی طرح سے منظم علاج کے ساتھ، امکانات مختلف ہیں. جدید ادویات سوجن کو کم کر سکتی ہیں اور مزید نقصان کو سست یا روک سکتی ہیں، اور بہت سے لوگ سالوں تک آرام سے متحرک رہتے ہیں۔ کچھ لوگ ایسی حالت میں پہنچتے ہیں جہاں ان کی بیماری خاموش ہوتی ہے، جسے ڈاکٹر معافی کہتے ہیں۔ اگر کوئی جوڑ پہلے سے ہی بری طرح نقصان پہنچا ہوا ہے تو، جوڑ کی تبدیلی کی سرجری اب بھی درد کو کم کر سکتی ہے اور جوڑ کے کام کو بہتر بنا سکتی ہے، جیسا کہ یہ پہننے اور پھاڑ کے آرتھرائٹس کے لئے کرتا ہے۔

آپریشن کے بعد کیا ہوتا ہے؟ ہپ کی تبدیلی کے بعد ، رومٹوائڈ گٹھیا والے افراد عام طور پر کم درد اور بہتر کام کی اطلاع دیتے ہیں ، جو لباس اور آنسو گٹھیا والے لوگوں کی طرح ہوتا ہے ، حالانکہ پیچیدگیوں یا ٹریک کے نیچے مزید سرجری کا کچھ زیادہ امکان ہوتا ہے۔ ٹخنوں کی تبدیلی کے بعد ، روماتیوڈ گٹھیا والے افراد دوسرے قسم کے گٹھیا والے افراد کے مقابلے میں روزانہ کے اسکور میں کم بہتری کی اطلاع دیتے ہیں ، لیکن وہ اب بھی جہاں سے شروع ہوئے تھے اس کے مقابلے میں بہتری لاتے ہیں۔ کلائی کی تبدیلی نے آپریشن کے بعد 10 سال تک اچھے نتائج دکھائے ہیں۔ آپ کا ڈاکٹر آپ کو بتائے گا کہ یہ آپ کے مخصوص جوڑ کے لئے کیا مطلب ہے.

آپ کے جوڑوں کو متحرک رکھنے اور آپریشن کی ضرورت پڑنے پر آپ کے جوڑوں کی مستقل طبی دیکھ بھال کی بنیاد پر ایک رات میں ٹھیک ہونے کے بجائے ہفتوں اور مہینوں میں آہستہ آہستہ پیش رفت ہوتی ہے۔

کسی سے کب ملنا ہے

سوزش والی گٹھائی ایک ایسی حالت ہے جس کا آپ کے جی پی اور رومیٹولوجی ٹیم روزانہ انتظام کرتے ہیں ، لہذا آپ کی زیادہ تر تقررییں ان کے ساتھ ہوں گی۔ اگر آپ کے جوڑوں میں دواؤں کے باوجود درد، سوجن یا سخت رہتا ہے، یا اگر آپ کے جوڑوں کی شکل تبدیل ہوگئی ہے یا روزمرہ کے کاموں کو بہت مشکل بنا رہا ہے تو ماہر کی جانچ پڑتال کے لئے پوچھیں. آپ کا ڈاکٹر یہ چیک کرنے کا بھی بندوبست کر سکتا ہے کہ آپ کا موجودہ علاج کتنا اچھا کام کر رہا ہے۔

اگر آپ کے ایک مشترکہ میں گرمی، لالچ یا سوجن پیدا ہو جائے جو آپ کے معمول کے فلیکس سے کہیں زیادہ تکلیف دہ ہے، خاص طور پر اگر آپ بخار یا بیمار محسوس کرتے ہیں تو فوری طور پر اپنے ڈاکٹر سے رجوع کریں۔ ایک سوجن جوڑ کبھی کبھی انفیکشن ہو سکتا ہے، اور اس کی فوری تشخیص کی ضرورت ہے.

اگر آپ کو بخار کے ساتھ ایک گرم، شدید دردناک مشترکہ ہے اور آپ کو فوری طور پر GP دیکھ بھال نہیں مل سکتی ہے، یا اگر آپ مشترکہ کے ارد گرد سرخیاں پھیلانے کے ساتھ عام طور پر بیمار محسوس کرتے ہیں تو ایک ہنگامی محکمہ میں جائیں.

Reviewed by Kieran Hirpara · 13 June 2026.

Want the clinical detail? Read the clinician version.

Talk to your treating clinician for advice specific to you.

For an appointment with the CQ Hand + Upper Limb team, ask your GP about a referral or visit www.cqupperlimb.com.

Evidence & references

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Overview

  • The volume of total joint arthroplasty procedures in patients with rheumatoid arthritis has trended markedly upward over the past decade, with a sharp increase after 2015 [1].
  • Inflammatory arthritis is associated with higher rates of medical and surgical complications compared to osteoarthritis in patients undergoing anatomic or reverse total shoulder arthroplasty [9].
  • Following total shoulder arthroplasty, patients with rheumatoid arthritis are at higher risk of systemic and joint-related complications compared to patients with primary osteoarthritis [5].
  • Despite comparable complication rates between rheumatoid arthritis and non-rheumatoid arthritis cohorts, rheumatoid arthritis patients have increased revision rates in total elbow arthroplasty [2].
  • Following primary total hip arthroplasty, patients with rheumatoid arthritis can expect reduced pain and improved functional outcomes similar to those with osteoarthritis [6].
  • Patients with rheumatoid arthritis undergoing primary total hip arthroplasty may be at an increased risk of complications and revision surgery [6].
  • In the largest single-institution study to date, patients with rheumatoid arthritis reported poorer patient-reported outcome scores compared with osteoarthritis and posttraumatic arthritis groups after total ankle arthroplasty [7].
  • Patients with rheumatoid arthritis experienced functional outcome improvement from the preoperative baseline following total ankle arthroplasty [7].
  • Denosumab demonstrates promising efficacy in maintaining bone health and preventing joint damage in rheumatoid arthritis patients with coexisting osteoporosis [3].
  • Cutaneous psoriasis and psoriatic arthritis are associated with higher rates of infections and all-cause revisions following total hip arthroplasty [13].

Background & Causes

  • Patients with rheumatoid arthritis undergoing elective hand surgery who continue perioperative biologic disease-modifying antirheumatic drugs do not experience significant increases in risks of wound healing failures or surgical site infections [15].
  • Discontinuation of antiviral prophylaxis correlates with a high prevalence of hepatitis B virus reactivation in rheumatoid arthritis patients with a hepatitis B virus carrier state [17].
  • Preclinical evidence supports an antioxidant, anti-inflammatory, antinociceptive, cartilage- and bone-protective effect of calcitonin in rheumatoid arthritis and osteoarthritis [16].
  • Tectochrysin may act as a novel rheumatoid arthritis therapeutic agent via macrophage JAK/STAT pathway inhibition [14].

Symptoms & Presentation

  • Patients with rheumatoid arthritis who have undergone shoulder arthroplasty experience reduced pain and improved function [10].
  • In patients with rheumatoid arthritis, negative affect moderates pain following shoulder arthroplasty [10].
  • Patients with rheumatoid arthritis report poorer patient-reported outcome scores compared with osteoarthritis and posttraumatic arthritis groups following total ankle arthroplasty [7].
  • Patients with rheumatoid arthritis experience functional outcome improvement from the preoperative baseline following total ankle arthroplasty [7].
  • Total knee arthroplasty in patients with rheumatoid arthritis yields significant improvement in physician- and patient-reported outcomes [12].
  • Patients with rheumatoid arthritis can expect reduced pain and improved functional outcomes similar to those with osteoarthritis following primary total hip arthroplasty [6].
  • Patient-reported functional outcomes at 6 months following total elbow arthroplasty were significantly lower in the fracture group compared to osteoarthritis and rheumatoid arthritis groups [11].
  • The Kudo type-5 prosthesis demonstrated satisfactory results in patients with rheumatoid arthritis over a minimum 10-year follow-up period [18].
  • Failures of the Kudo type-5 prosthesis occurred to some extent over a long-term follow-up period in patients with rheumatoid arthritis [18].
  • HandScan optical imaging can reliably identify ultrasound-defined remission in rheumatoid arthritis at the joint level with good sensitivity and high positive predictive value [21].
  • DAS-OST can determine ultrasound remission in rheumatoid arthritis at the patient level but with lower performance than HandScan [21].

Management

Non-Operative

  • Rheumatoid arthritis is a chronic, systemic, inflammatory disease that most often involves the small joints of the hands and feet, although any synovial joint can be affected [19].
  • Rheumatoid arthritis affects 1% to 2% of the world population, with a female-to-male ratio of 2.5:1 [19].
  • Adult rheumatoid arthritis is usually polyarticular, while systemic involvement in visceral organs or eyes is rare [19].
  • The test for rheumatoid factor in adults is positive in 70% to 80% of patients diagnosed with rheumatoid arthritis [19].
  • A patient is considered to have rheumatoid arthritis if at least four of the seven American Rheumatism Association criteria have been present for at least 6 weeks [19].
  • The clinical picture of rheumatoid arthritis is characterized by synovitis and joint destruction, with synovitis tending to wax and wane [19].
  • Joint destruction in rheumatoid arthritis starts within the first or second year of the disease and continues to progress [19].
  • Radiographic signs of rheumatoid arthritis destruction include joint space narrowing, periarticular erosions, and subchondral osteopenia [19].
  • Structural damage in rheumatoid arthritis manifests as pain with activity and deformity [19].
  • Treatment of the early stages of rheumatoid arthritis is primarily medical, although physical and occupational therapy can be helpful [19].
  • Pharmacologic agents used in rheumatoid arthritis include nonsteroidal antiinflammatory drugs, corticosteroids, methotrexate, and biologic agents [19].
  • Biologic agents are recombinant proteins that generally target an inflammatory cytokine, such as tumor necrosis factor [19].
  • Biologic agents have shown excellent results in rheumatoid arthritis treatment [19].
  • Biologic agents inhibit the immune system and cause an increased risk of infection in patients taking them [19].
  • Jämsen et al. found a 48% decrease in the number of primary arthroplasties performed for rheumatoid arthritis between 1995 and 2010, attributed to the effectiveness of improved medical management [19].
  • There is preclinical evidence for an antioxidant, anti-inflammatory, antinociceptive, cartilage- and bone-protective effect of calcitonin in rheumatoid arthritis and osteoarthritis [16].
  • Tectochrysin may be a novel rheumatoid arthritis therapeutic agent acting via macrophage JAK/STAT pathway inhibition, with promising clinical potential [14].
  • Supervised high-intensity interval training and strength exercise appear to be feasible and well tolerated by patients and could be recommended to improve cardiovascular and physical health in patients with well-controlled rheumatoid arthritis [20].

Perioperative Medical Management

  • Patients with rheumatoid arthritis on corticosteroids generally require preoperative “stress” dosages of hydrocortisone [19].
  • Agents that inhibit the immune system should be withheld at least 1 week before and 1 week after a surgical procedure in patients with rheumatoid arthritis [19].
  • Among patients with rheumatoid arthritis undergoing elective hand surgery, perioperative biologic disease-modifying antirheumatic drug continuation was not associated with significant increases in risks of wound healing failures or surgical site infections [15].

Operative

  • The volume of total joint arthroplasty procedures conducted in patients with rheumatoid arthritis has trended markedly upward over the past decade, with a sharp increase after 2015 [1].
  • Although patients with rheumatoid arthritis may be at an increased risk of complications and revision surgery, patients can expect reduced pain and improved functional outcomes similar to those with osteoarthritis following primary total hip arthroplasty [6].
  • Following total shoulder arthroplasty, patients with rheumatoid arthritis should be considered at higher risk of systemic and joint-related complications compared to patients with primary osteoarthritis [5].
  • Shoulder arthroplasty in patients with rheumatoid arthritis reduces pain and improves function [10].
  • In the largest single-institution study to date, patients with rheumatoid arthritis reported poorer patient-reported outcome scores compared with osteoarthritis and posttraumatic arthritis groups but experienced functional outcome improvement from the preoperative baseline following total ankle arthroplasty [7].
  • Despite comparable complication rates between rheumatoid arthritis and non-rheumatoid arthritis cohorts, further investigation into the underlying mechanisms of increased revision rates in rheumatoid arthritis patients is warranted following total elbow arthroplasty [2].
  • Patient-reported functional outcomes at 6 months were significantly lower in the fracture group compared to osteoarthritis and rheumatoid arthritis groups following total elbow arthroplasty [11].
  • Comparative outcomes of robot-assisted versus conventional total knee arthroplasty provide important evidence for selecting surgical methods in rheumatoid osteoarthritis [4].

Key Considerations

Perioperative Risk and Complications

  • Patients with rheumatoid arthritis may be at an increased risk of complications and revision surgery following primary total hip arthroplasty [6].
  • Despite comparable complication rates between rheumatoid arthritis and non-RA cohorts in total elbow arthroplasty, further investigation into the underlying mechanisms of increased revision rates in RA patients is warranted [2].

Functional Outcomes and Patient-Reported Measures

  • In the largest single-institution study to date, patients with rheumatoid arthritis reported poorer patient-reported outcome scores compared with osteoarthritis and posttraumatic arthritis groups following total ankle arthroplasty [7].

Long-Term Survivorship and Device Performance

  • The Kudo type-5 prosthesis demonstrated satisfactory results in patients with rheumatoid arthritis, although failures occurred to some extent over a long-term follow-up period [18].
  • Radiolunate arthrodesis in patients with rheumatoid arthritis maintained good clinical results and corrected alignment during long-term follow-up [22].

Surgical Technique Selection

Patient Education

  • Physicians should provide information regarding the treatment of rheumatoid arthritis to patients in counseling and education materials [8].

Pharmacologic Management

Key Evidence

  • [L4] The volume of total joint arthroplasty (TJA) procedures conducted in patients with rheumatoid arthritis has trended markedly upward over the past decade, with a sharp increase after 2015. [1] (10.5435/jaaosglobal-d-22-00209)
  • [L3] Despite comparable complication rates between RA and non-RA cohorts, further investigation into the underlying mechanisms of increased revision rates in RA patients is warranted. [2] (10.1016/j.jse.2024.12.032)
  • [L1] Denosumab demonstrates promising efficacy in maintaining bone health and preventing joint damage in rheumatoid arthritis patients with coexisting osteoporosis. [3] (10.1186/s12891-025-08688-8)
  • [L3] This provides important evidence for selecting surgical methods in rheumatoid osteoarthritis. [4] (10.1186/s13018-026-06703-9)
  • [L3] Following TSA, RA patients should be considered at higher risk of systemic and joint-related complications compared to patients with primary OA. [5] (10.5397/cise.2024.00374)
  • [L3] Although patients with rheumatoid arthritis may be at an increased risk of complications and revision surgery, patients can expect reduced pain and improved functional outcomes similar to those with osteoarthritis following primary THA. [6] (10.5435/jaaos-d-24-00656)
  • [L3] In the largest single-institution study to date, patients with RA reported poorer PRO scores compared with the OA and posttraumatic arthritis groups but experienced functional outcome improvement from the preoperative baseline. [7] (10.2106/jbjs.24.00048)
  • [L4] Physicians should provide such information to patients with RA in the counseling and education materials. [8] (10.1371/journal.pone.0285869)
  • [L3] Inflammatory arthritis represents a distinctly morbid risk profile compared to osteoarthritis patients with multiple increased surgical and postoperative medical complications in patients undergoing aTSA and rTSA. [9] (10.1016/j.jse.2023.09.014)
  • [L3] Shoulder arthroplasty in patients with rheumatoid arthritis reduces pain and improves function. [10] (10.1186/s13018-025-06109-z)
  • [L3] Patient-reported functional outcomes at 6 months were significantly lower in the fracture group compared to osteoarthritis and rheumatoid arthritis groups. [11] (10.1016/j.jse.2026.01.019)
  • [L3] Total knee arthroplasty in patients who have RA yields significant improvement in physician- and patient-reported outcomes. [12] (10.1016/j.arth.2026.03.021)
  • [L3] In particular, both PsC and PsA were associated with higher rates of infections and all-cause revisions. [13] (10.1016/j.arth.2026.03.054)
  • [L5] Tectochrysin may be a novel RA therapeutic agent, likely acting via macrophage JAK/STAT pathway inhibition, with promising clinical potential. [14] (10.1186/s13018-025-06481-w)
  • [L2] Among patients with RA undergoing elective hand surgery, perioperative bDMARD continuation was not associated with significant increases in risks of wound healing failures or SSIs. [15] (10.1016/j.jhsa.2026.03.003)
  • [L1] There is preclinical evidence for an antioxidant, anti-inflammatory, antinociceptive, cartilage- and bone-protective effect of CT in RA and OA. [16] (10.1530/eor-23-0133)
  • [L4] Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state. [17] (10.1186/1471-2474-15-449)
  • [L4] Although the Kudo type-5 prosthesis demonstrated satisfactory results in patients with RA, failures occurred to some extent over a long-term follow-up period. [18] (10.1016/j.jse.2024.10.025)
  • [L1] Supervised HIIT and strength exercise appear to be feasible and well tolerated by patients and could be recommended to improve cardiovascular and physical health in patients with well-controlled RA. [20] (10.1136/bjsports-2024-108369)
  • [L3] HandScan is able to reliably identify US-defined remission in RA at the joint level, with a good sensitivity and high PPV, while at the patient level, DAS-OST can also determine US remission but with lower performance. [21] (10.1186/s12891-024-07472-4)
  • [L4] Radiolunate arthrodesis in patients with RA maintained good clinical results and corrected alignment, even during long-term follow-up. [22] (10.1016/j.jhsa.2022.11.014)

References

[1] Trends in Total Joint Arthroplasty Among Patients With Rheumatoid Arthritis: The Effect of Recent Disease Modifying Antirheumatic Drug Utilization Guidelines. JAAOS: Global Research and Reviews. 2022. DOI: 10.5435/jaaosglobal-d-22-00209

[2] Rates of long-term risk of revision and complications in total elbow arthroplasty in patients with rheumatoid arthritis: a propensity score-matched analysis. Journal of Shoulder and Elbow Surgery. 2025. DOI: 10.1016/j.jse.2024.12.032

[3] Efficacy of denosumab in treatment of osteoporosis in patients with rheumatoid arthritis: a meta-analysis of randomized controlled trial. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-08688-8

[4] Comparative outcomes of robot-assisted versus conventional TKA in rheumatoid arthritis patients. Journal of Orthopaedic Surgery and Research. 2026. DOI: 10.1186/s13018-026-06703-9

[5] Rheumatoid arthritis is associated with higher 90-day systemic complications compared to osteoarthritis after total shoulder arthroplasty: a cohort study. Clinics in Shoulder and Elbow. 2024. DOI: 10.5397/cise.2024.00374

[6] Patient-Reported Outcome Measures After Direct Anterior Total Hip Arthroplasty Are Comparable Between Patients With Rheumatoid Arthritis and Osteoarthritis: A Propensity-Matched Analysis. Journal of the American Academy of Orthopaedic Surgeons. 2024. DOI: 10.5435/jaaos-d-24-00656

[7] Complication Rates and Functional Outcomes After Total Ankle Arthroplasty in Patients with Rheumatoid Arthritis. Journal of Bone and Joint Surgery. 2025. DOI: 10.2106/jbjs.24.00048

[8] Internet search analysis on the treatment of rheumatoid arthritis: What do people ask and read online?. PLOS ONE. 2023. DOI: 10.1371/journal.pone.0285869

[9] Shoulder arthroplasty for inflammatory arthritis is associated with higher rates of medical and surgical complications: a nationwide matched cohort analysis from 2016-2020. Journal of Shoulder and Elbow Surgery. 2024. DOI: 10.1016/j.jse.2023.09.014

[10] The moderating role of negative affect on pain in patients with rheumatoid arthritis who have undergone shoulder arthroplasty. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06109-z

[11] A comparison of survivorship and functional outcomes for total elbow arthroplasty performed for distal humerus fracture, rheumatoid arthritis, and osteoarthritis, a New Zealand Joint Registry study. Journal of Shoulder and Elbow Surgery. 2026. DOI: 10.1016/j.jse.2026.01.019

[12] Patient-Reported Outcomes and Satisfaction Following Total Knee Arthroplasty in Rheumatoid Arthritis: An Observational Cohort Study. The Journal of Arthroplasty. 2026. DOI: 10.1016/j.arth.2026.03.021

[13] Outcomes Following Total Hip Arthroplasty in Patients with Cutaneous Psoriasis and Psoriatic Arthritis. The Journal of Arthroplasty. 2026. DOI: 10.1016/j.arth.2026.03.054

[14] Targeting macrophage JAK3/STAT3 signaling with tectochrysin: a novel therapeutic strategy to ameliorate bone erosion and synovitis in rheumatoid arthritis. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06481-w

[15] Perioperative Biologic Disease-Modifying Antirheumatic Drugs, Risks of Infections, and Wound Complications in Patients With Rheumatoid Arthritis Undergoing Elective Hand Surgery. The Journal of Hand Surgery. 2026. DOI: 10.1016/j.jhsa.2026.03.003

[16] Calcitonin treatment for osteoarthritis and rheumatoid arthritis – a systematic review and meta-analysis of preclinical data. EFORT Open Reviews. 2024. DOI: 10.1530/eor-23-0133

[17] Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. BMC Musculoskeletal Disorders. 2014. DOI: 10.1186/1471-2474-15-449

[18] Long-term follow-up study of Kudo type-5 elbow prosthesis in patients with rheumatoid arthritis: minimum 10-year clinical outcomes. Journal of Shoulder and Elbow Surgery. 2025. DOI: 10.1016/j.jse.2024.10.025

[19] Campbell S Operative Orthopaedics 4 Volume Set. SOFT-TISSUE PROCEDURES AND OSTEOTOMIES ABOUT THE KNEE > RHEUMATOID ARTHRITIS OF THE KNEE > ADULT-ONSET RHEUMATOID ARTHRITIS.

[20] High-intensity interval training improves cardiovascular and physical health in patients with rheumatoid arthritis: a multicentre randomised controlled trial. British Journal of Sports Medicine. 2024. DOI: 10.1136/bjsports-2024-108369

[21] Optical imaging (HandScan) can identify ultrasound remission in rheumatoid arthritis. BMC Musculoskeletal Disorders. 2024. DOI: 10.1186/s12891-024-07472-4

[22] Radiolunate Arthrodesis in the Rheumatoid Wrist: A Retrospective Clinical and Radiologic Long-Term Follow-Up. The Journal of Hand Surgery. 2024. DOI: 10.1016/j.jhsa.2022.11.014

Creative Commons BY-NC 4.0

CC Creative Commons licence
BY Attribution — you must credit the source
NC NonCommercial — not for commercial use

Attribution-NonCommercial 4.0 International

Creative Commons Corporation ("Creative Commons") is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an "as-is" basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC- licensed material, or material used under an exception or limitation to copyright. More considerations for licensors: wiki.creativecommons.org/Considerations_for_licensors

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor's permission is not necessary for any reason--for example, because of any applicable exception or limitation to copyright--then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public: wiki.creativecommons.org/Considerations_for_licensees

Creative Commons Attribution-NonCommercial 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NonCommercial 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 -- Definitions.

a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

d. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

f. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.

i. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.

j. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

k. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

l. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 -- Scope.

a. License grant.

1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and

b. produce, reproduce, and Share Adapted Material for NonCommercial purposes only.

2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

3. Term. The term of this Public License is specified in Section 6(a).

4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a) (4) never produces Adapted Material.

5. Downstream recipients.

a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

2. Patent and trademark rights are not licensed under this Public License.

3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.

Section 3 -- License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

a. Attribution.

1. If You Share the Licensed Material (including in modified form), You must:

a. retain the following if it is supplied by the Licensor with the Licensed Material:

i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

ii. a copyright notice;

iii. a notice that refers to this Public License;

iv. a notice that refers to the disclaimer of warranties;

v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 -- Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only;

b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 -- Disclaimer of Warranties and Limitation of Liability.

a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.

b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.

c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 -- Term and Termination.

a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 -- Other Terms and Conditions.

a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 -- Interpretation.

a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.

Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark "Creative Commons" or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.